These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 16402886)

  • 1. Do drug formulary policies reflect evidence of value?
    Neumann PJ; Lin PJ; Greenberg D; Berger M; Teutsch S; Mansley E; Weinstein MC; Rosen AB
    Am J Manag Care; 2006 Jan; 12(1):30-6. PubMed ID: 16402886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The case for a value-based formulary: striving for total lowest net cost.
    Weart W; Bauman GR
    Manag Care Interface; 2007 Apr; 20(4):42-7. PubMed ID: 17474330
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incorporating quality of life data into managed care formulary decisions: a case study with salmeterol.
    Bukstein DA
    Am J Manag Care; 1997 Nov; 3(11):1701-6. PubMed ID: 10178468
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using clinical evidence to manage pharmacy benefits: experiences of six states.
    Bergman D; Hoadley J; Kaye N; Crowley J; Hostetter M
    Issue Brief (Commonw Fund); 2006 Mar; (899):1-14. PubMed ID: 16562357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Formulary tier placement for commonly prescribed branded drugs: benchmarking and creation of a preferred placement index.
    Mullins CD; Palumbo FB; Saba M
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):377-84. PubMed ID: 17567239
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A call for fairness in formulary decisions.
    Levinson W; Laupacis A
    Arch Intern Med; 2006 Jan; 166(1):16-8. PubMed ID: 16401806
    [No Abstract]   [Full Text] [Related]  

  • 7. Formulary tiers, medication cost sharing, and transparency in bronze and silver qualified health plans in 2014 vs 2018.
    Hung A; Sauvageau G
    J Manag Care Spec Pharm; 2021 Oct; 27(10):1332-1340. PubMed ID: 34595951
    [No Abstract]   [Full Text] [Related]  

  • 8. Three-tiered-copayment drug coverage and use of nonsteroidal anti-inflammatory drugs.
    Briesacher B; Kamal-Bahl S; Hochberg M; Orwig D; Kahler KH
    Arch Intern Med; 2004 Aug 9-23; 164(15):1679-84. PubMed ID: 15302639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A cost-utility analysis of chronic spinal pain treatment outcomes: converting SF-36 data into quality-adjusted life years.
    Hatten AL; Gatchel RJ; Polatin PB; Stowell AW
    Clin J Pain; 2006 Oct; 22(8):700-11. PubMed ID: 16988566
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of health-related quality of life information in managed care formulary decision-making.
    Wu WK; Sause RB; Zacker C
    Res Social Adm Pharm; 2005 Dec; 1(4):579-98. PubMed ID: 17138497
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incentive formularies and changes in prescription drug spending.
    Landon BE; Rosenthal MB; Normand SL; Spettell C; Lessler A; Underwood HR; Newhouse JP
    Am J Manag Care; 2007 Jun; 13(6 Pt 2):360-9. PubMed ID: 17567237
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of patient and plan design factors on switching to preferred statin therapy.
    Cox ER; Kulkarni A; Henderson R
    Ann Pharmacother; 2007 Dec; 41(12):1946-53. PubMed ID: 17971409
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy.
    Goldman DP; Joyce GF; Karaca-Mandic P
    Am J Manag Care; 2006 Jan; 12(1):21-8. PubMed ID: 16402885
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug pricing and value in oncology.
    Danzon PM; Taylor E
    Oncologist; 2010; 15 Suppl 1():24-31. PubMed ID: 20237214
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differences in the cost of antidepressants across state Medicaid programs.
    Kelton CM; Rebelein RP; Heaton PC; Ferrand Y; Guo JJ
    J Ment Health Policy Econ; 2008 Mar; 11(1):33-47. PubMed ID: 18424875
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessing Medicare prescription drug plans in four states: balancing cost and access.
    Heaton E; Carino T; Dix H
    Issue Brief (Commonw Fund); 2006 Aug; 22():1-14. PubMed ID: 16933399
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Consumer attitudes and factors related to prescription switching decisions in multitier copayment drug benefit plans.
    Ganther-Urmie JM; Nair KV; Valuck R; McCollum M; Lewis SJ; Turpin RS
    Am J Manag Care; 2004 Mar; 10(3):201-8. PubMed ID: 15032257
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quality of clinical and economic evidence in dossier formulary submissions.
    Colmenero F; Sullivan SD; Palmer JA; Brauer CA; Bungay K; Watkins J; Neumann PJ
    Am J Manag Care; 2007 Jul; 13(7):401-7. PubMed ID: 17620035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Formulary-control procedures in a staff-model health maintenance organization.
    Lyon RA
    Am J Hosp Pharm; 1990 Feb; 47(2):340-2. PubMed ID: 2106782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Operation, formulary decision-making activities of a P & T Committee in a managed care setting.
    Adams J; Richardson J
    Hosp Formul; 1991 Apr; 26(4):291-4, 300-1. PubMed ID: 10109798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.